RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:498228

Phyllodes tumor of the prostate

low confidenceDisorder

Also known as: Cystic epithelial-stromal tumors of the prostate · Cystosarcoma phyllodes of the prostate · Phyllodes type of atypical prostatic hyperplasia

Publications

2,392

Trials

0

Interventional, condition-specific

Researchers

1,359

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare urogenital tumor characterized by stromal and epithelial components forming cysts lined by hyperplastic epithelium in a cellular or sarcomatoid stroma. The tumors may be clinically benign or malignant and tend to recur after transurethral resection. Metastatic spread is to lungs, bone, and liver. Patients may present with obstructive voiding symptoms, dysuria, hematuria, urinary retention, or a palpable abdominal mass. The prostate is palpably enlarged but feels soft and spongy.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (13)

cystosarcoma phyllodes of prostate · cystosarcoma phyllodes of the prostate · phyllodes neoplasm of prostate · phyllodes neoplasm of the prostate · phyllodes tumor of prostate · phyllodes tumor of the prostate · phyllodes tumour of prostate · phyllodes tumour of the prostate · prostate cystosarcoma phyllodes · prostate gland phyllodes tumor · prostate gland phyllodes tumour · prostate phyllodes neoplasm · prostate phyllodes tumor

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,392 matched papers (1,165 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 3 for broader category phyllodes tumor

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

2,392

2,392 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

2,392 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,165 in the last 10 years · low confidence

Phrase hits: 2,392 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,359

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Antonarakis ES4 papers · 2026

    Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.

    Papers in Europe PMC
  2. 02
    Hodgson K4 papers · 2026

    Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.

    Papers in Europe PMC
  3. 03
    Munkley J4 papers · 2026

    Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.

    Papers in Europe PMC
  4. 04
    Wang Y4 papers · 2026

    Department of Radiology, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China.

    Papers in Europe PMC
  5. 05
    Beatson R3 papers · 2026

    Comprehensive Cancer Centre, King's College London, London.

    Papers in Europe PMC
  6. 06
    Blencoe L3 papers · 2026

    Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.

    Papers in Europe PMC
  7. 07
    Bostwick DG3 papers · 2021

    Bostwick Laboratories, A Division of Poplar Healthcare, Orlando, FL, USA. Electronic address: dbostwick@grangergenetics.com.

    Papers in Europe PMC
  8. 08
    Cheng L3 papers · 2020

    Department of Neurology, Jiujiang University Clinical Medical College, Jiujiang, China.

    Papers in Europe PMC
  9. 09
    Jochumsen MR3 papers · 2026

    Department of Nuclear Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200, Aarhus, Denmark. madsjoch@rm.dk.

    Papers in Europe PMC
  10. 10
    Li X3 papers · 2025

    Department of Urology, Institute of Urology, Peking University First Hospital, Peking University, National Urological Cancer Center, Beijing, 100034, China. pineneedle@sina.com.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 3 trials are registered for phyllodes tumor, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

low confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

3 interventional trials matched phyllodes tumor, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: phyllodes tumor

3

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Phyllodes tumor of the prostate" OR "Phyllodes tumor of prostate" OR "Cystic epithelial-stromal tumors of the prostate" OR "Cystic epithelial-stromal tumors of prostate" OR "Cystosarcoma phyllodes of the prostate" OR "Cystosarcoma phyllodes of prostate" OR "Phyllodes type of atypical prostatic hyperplasia" OR "Phyllodes type of the atypical prostatic hyperplasia" OR "phyllodes neoplasm of prostate" OR "phyllodes neoplasm of the prostate" OR "phyllodes tumour of prostate" OR "phyllodes tumour of the prostate" OR "prostate cystosarcoma phyllodes" OR "prostate gland phyllodes tumor" OR "prostate gland phyllodes tumour" OR "prostate phyllodes neoplasm" OR "prostate phyllodes tumor"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Phyllodes tumor of the prostate" OR "Phyllodes tumor of prostate" OR "Cystic epithelial-stromal tumors of the prostate" OR "Cystic epithelial-stromal tumors of prostate" OR "Cystosarcoma phyllodes of the prostate" OR "Cystosarcoma phyllodes of prostate" OR "Phyllodes type of atypical prostatic hyperplasia" OR "Phyllodes type of the atypical prostatic hyperplasia" OR "phyllodes neoplasm of prostate" OR "phyllodes neoplasm of the prostate" OR "phyllodes tumour of prostate" OR "phyllodes tumour of the prostate" OR "prostate cystosarcoma phyllodes" OR "prostate gland phyllodes tumor" OR "prostate gland phyllodes tumour" OR "prostate phyllodes neoplasm" OR "prostate phyllodes tumor"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"phyllodes tumor"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2392) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T17:37:48.607Z